- Report
- February 2024
- 112 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2023
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2020
- 153 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- April 2023
- 326 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- September 2024
- 239 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- September 2024
- 69 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- August 2023
- 78 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- July 2023
- 84 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- August 2024
- 199 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- August 2024
- 98 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- July 2024
- 280 Pages
Global
From €2534EUR$2,655USD£2,123GBP
- Book
- February 2018
- 448 Pages

Fluorouracil (5-FU) is a chemotherapy drug used in the treatment of cancer. It is a pyrimidine analog, which interferes with the synthesis of DNA and RNA, leading to cell death. It is used to treat a variety of cancers, including breast, colorectal, gastric, pancreatic, and head and neck cancers. It is also used in combination with other drugs to treat advanced or metastatic cancers. Fluorouracil is administered intravenously or topically, depending on the type of cancer being treated.
Fluorouracil is a widely used drug in the oncology market, and is often used in combination with other drugs to treat advanced or metastatic cancers. It is a generic drug, and is available in both branded and generic formulations. The branded formulations are typically more expensive than the generic versions.
Companies in the Fluorouracil market include Pfizer, Merck, Bristol-Myers Squibb, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more